Literature DB >> 29364502

ARRDC3 suppresses colorectal cancer progression through destabilizing the oncoprotein YAP.

Xu Shen1, Xiaohan Sun1, Bing Sun2, Tao Li2, Guoliang Wu2, Yuantao Li2, Lai Chen3, Qingxin Liu1, Meng Cui2, Zizhang Zhou1.   

Abstract

Although colorectal cancer (CRC) is a prevalent malignancy of the digestive system, the underlying mechanisms of CRC tumorigenesis are still elusive. Arrestin-related domain-containing protein-3 (ARRDC3) has been reported to promote lysosome-mediated protein degradation. In the present study, we find that the expression of ARRDC3 is downregulated in CRC specimens. Mechanistically, we reveal that ARRDC3 binds and decreases expression of the oncoprotein YAP, the cotranscription factor of the Hippo pathway. The regulation of the Hippo pathway by ARRDC3 is conserved from Drosophila to mammals. Furthermore, we demonstrate that ARRDC3 plays an anti-oncogenic role in CRC progression by promoting YAP degradation. Finally, we show that ARRDC3 increases the sensitivity of CRC cells toward chemotherapeutic drugs. Taken together, our findings point to ARRDC3 as a potential target for CRC treatment.
© 2018 Federation of European Biochemical Societies.

Entities:  

Keywords:  ARRDC3; Hippo pathway; colorectal cancer

Mesh:

Substances:

Year:  2018        PMID: 29364502     DOI: 10.1002/1873-3468.12986

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

Review 1.  The α-Arrestin ARRDC3 Is an Emerging Multifunctional Adaptor Protein in Cancer.

Authors:  Helen Wedegaertner; Wen-An Pan; Carlos C Gonzalez; David J Gonzalez; JoAnn Trejo
Journal:  Antioxid Redox Signal       Date:  2022-01-04       Impact factor: 7.468

Review 2.  α-Arrestins and Their Functions: From Yeast to Human Health.

Authors:  Kacper Zbieralski; Donata Wawrzycka
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

3.  A Potential Indicator ARRDC2 Has Feasibility to Evaluate Prognosis and Immune Microenvironment in Ovarian Cancer.

Authors:  Mengjun Zhang; Yunduo Liu; Yuan Liu; Siyu Hou; Hao Li; Ying Ma; Can Wang; Xiuwei Chen
Journal:  Front Genet       Date:  2022-05-18       Impact factor: 4.772

4.  α-Arrestin ARRDC3 tumor suppressor function is linked to GPCR-induced TAZ activation and breast cancer metastasis.

Authors:  Aleena K S Arakaki; Wen-An Pan; Helen Wedegaertner; Ivette Roca-Mercado; Logan Chinn; Taranjit S Gujral; JoAnn Trejo
Journal:  J Cell Sci       Date:  2021-04-22       Impact factor: 5.285

5.  Long non-coding RNA DHRS4 antisense RNA 1 inhibits ectopic endometrial cell proliferation, migration, and invasion in endometriosis by regulating microRNA-139-5p expression.

Authors:  Xuan Cui; Shisan Zhou; Yongtao Lin
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

6.  Usp7 regulates Hippo pathway through deubiquitinating the transcriptional coactivator Yorkie.

Authors:  Xiaohan Sun; Yan Ding; Meixiao Zhan; Yan Li; Dongqing Gao; Guiping Wang; Yang Gao; Yong Li; Shian Wu; Ligong Lu; Qingxin Liu; Zizhang Zhou
Journal:  Nat Commun       Date:  2019-01-24       Impact factor: 14.919

Review 7.  Roles of Membrane and Vesicular Traffic in Regulation of the Hippo Pathway.

Authors:  Shilpi Verghese; Ken Moberg
Journal:  Front Cell Dev Biol       Date:  2020-01-10

8.  ARRDC3 as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer Based on Data Mining.

Authors:  Yanli Chen; Dan Tian; Xiaoqi Chen; Zhi Tang; Kuina Li; Zhijiong Huang; Yong Fu; Yanying Feng; Zhijun Yang
Journal:  Int J Gen Med       Date:  2021-03-22

9.  MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel.

Authors:  Jie Yan; Litong Shi; Shan Lin; Yi Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

10.  Hippo signaling suppresses tumor cell metastasis via a Yki-Src42A positive feedback loop.

Authors:  Yan Ding; Guiping Wang; Meixiao Zhan; Xiaohan Sun; Yanran Deng; Yunhe Zhao; Bin Liu; Qingxin Liu; Shian Wu; Zizhang Zhou
Journal:  Cell Death Dis       Date:  2021-12-03       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.